Millenco owns 6.9% of Alexion Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., July 27 - Alexion Pharmaceuticals, Inc. investors led by Millenco, LLC reported owning 2,525,310 shares, or 6.9% of the company's outstanding stock, at a cost of about $91,886,800, or an average of $36.38 per share.

The investor made a series of stock sales and purchases between May 29 and July 26, according to a schedule 13D filing with the Securities and Exchange Commission.

Alexion is a Cheshire, Conn.-based biotechnology company. It closed (Nasdaq: ALXN) at $57.18 on July 26.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.